

## Marlex - Recall of digoxin tablets

- On August 30, 2023, <u>Marlex announced</u> a consumer level recall of one lot of <u>digoxin</u> 0.125 mg and one lot of digoxin 0.25 mg tablets because of a label mix-up. Bottles of digoxin 0.125 mg are incorrectly labeled and contain digoxin 0.25 mg tablets. Bottles of digoxin 0.25 mg tablets are incorrectly labeled and contain digoxin 0.125 mg tablets.
  - Clinical Services identified potentially impacted members and will send notifications to the members and their prescribers.
  - o The member letter advises members to contact their pharmacy for a replacement.

Product Description	NDC Number	Lot Number (Exp Date)
Digoxin 0.125 mg tablet	10135-0747-01	E3810 (2/2025)
Digoxin 0.25 mg tablet	10135-0748-01	E3811 (2/2025)

- Digoxin is indicated for the treatment of heart failure in adults and pediatric patients, and for atrial fibrillation in adults.
- The mix-up in labels can cause either overdosing or underdosing in patients who unknowingly take the wrong dose. Patients who intend to take digoxin 0.125 mg, but unknowingly digoxin 0.25 mg would receive a super potent dose and can experience significant drug toxicity (mental disorientation, dizziness, blurred vision, memory loss and fainting) from the unintentional overdose.
- Patients who intend to take digoxin 0.25 mg, but unknowingly take digoxin 0.125 mg would
  receive a sub potent dose which may lead to loss of control of heart rate and potential heart failure
  exacerbation.
- Marlex has not received any reports of adverse events related to this recall.
- Anyone with the affected lot on hand should stop use and distribution and return to place of purchase.
- Contact Marlex at 1-302-328-3355 or 1-888-582-1953 for questions regarding this recall.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.